USP17L1
gene geneOn this page
Summary
USP17L1 (ubiquitin specific peptidase 17 like family member 1, HGNC:37182) is a protein-coding gene on chromosome 8p23.1, encoding Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 (Q7RTZ2). Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection.
Predicted to enable cysteine-type deubiquitinase activity. Predicted to be involved in regulation of apoptotic process and regulation of protein stability. Predicted to be located in endoplasmic reticulum. Predicted to be active in cytosol and nucleus.
Source: NCBI Gene 401447 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 1 total
- MANE Select transcript:
NM_001256873
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:37182 |
| Approved symbol | USP17L1 |
| Name | ubiquitin specific peptidase 17 like family member 1 |
| Location | 8p23.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000230549 |
| Ensembl biotype | protein_coding |
| Entrez | 401447 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000529559
RefSeq mRNA: 1 — MANE Select: NM_001256873
NM_001256873
CCDS: CCDS78298
Canonical transcript exons
ENST00000529559 — 1 exons
| Exon | Start | End |
|---|---|---|
| ENSE00002164335 | 7332387 | 7333979 |
Expression profiles
Bgee: expression breadth broad, 13 present calls, max score 47.73.
Top tissues by expression
113 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| ventricular zone | UBERON:0003053 | 47.73 | gold quality |
| cortical plate | UBERON:0005343 | 46.11 | gold quality |
| ganglionic eminence | UBERON:0004023 | 44.07 | silver quality |
| sural nerve | UBERON:0015488 | 37.52 | gold quality |
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| bone marrow cell | CL:0002092 | 36.16 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 35.45 | gold quality |
| C1 segment of cervical spinal cord | UBERON:0006469 | 35.10 | silver quality |
| skeletal muscle tissue | UBERON:0001134 | 34.84 | gold quality |
| right frontal lobe | UBERON:0002810 | 34.69 | silver quality |
| urinary bladder | UBERON:0001255 | 33.84 | gold quality |
| hypothalamus | UBERON:0001898 | 33.37 | silver quality |
| cerebral cortex | UBERON:0000956 | 32.59 | silver quality |
| substantia nigra | UBERON:0002038 | 32.47 | silver quality |
| brain | UBERON:0000955 | 32.42 | silver quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| muscle tissue | UBERON:0002385 | 32.13 | gold quality |
| bone marrow | UBERON:0002371 | 31.74 | gold quality |
| tonsil | UBERON:0002372 | 30.20 | gold quality |
| stromal cell of endometrium | CL:0002255 | 29.87 | gold quality |
| skin of abdomen | UBERON:0001416 | 29.36 | gold quality |
| placenta | UBERON:0001987 | 29.18 | gold quality |
| zone of skin | UBERON:0000014 | 28.88 | gold quality |
| liver | UBERON:0002107 | 28.71 | gold quality |
| islet of Langerhans | UBERON:0000006 | 28.31 | gold quality |
| skin of leg | UBERON:0001511 | 28.26 | gold quality |
| duodenum | UBERON:0002114 | 28.14 | gold quality |
| adrenal tissue | UBERON:0018303 | 27.84 | gold quality |
| ovary | UBERON:0000992 | 27.79 | silver quality |
| muscle of leg | UBERON:0001383 | 27.58 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | no | 0.33 |
Regulation
Is transcription factor: no
Cross-species orthologs
0 orthologs
Paralogs (71): USP2 (ENSG00000036672), USP28 (ENSG00000048028), USP36 (ENSG00000055483), USP13 (ENSG00000058056), USP33 (ENSG00000077254), USP40 (ENSG00000085982), USP48 (ENSG00000090686), USP14 (ENSG00000101557), USP11 (ENSG00000102226), USP10 (ENSG00000103194), USP31 (ENSG00000103404), USP42 (ENSG00000106346), USP5 (ENSG00000111667), USP4 (ENSG00000114316), USP9Y (ENSG00000114374), USP34 (ENSG00000115464), USP35 (ENSG00000118369), USP45 (ENSG00000123552), USP22 (ENSG00000124422), USP9X (ENSG00000124486), USP6 (ENSG00000129204), USP29 (ENSG00000131864), USP26 (ENSG00000134588), USP30 (ENSG00000135093), USP15 (ENSG00000135655), USP37 (ENSG00000135913), USP44 (ENSG00000136014), USP20 (ENSG00000136878), USP8 (ENSG00000138592), USP3 (ENSG00000140455), USP21 (ENSG00000143258), USP43 (ENSG00000154914), USP25 (ENSG00000155313), USP16 (ENSG00000156256), USP24 (ENSG00000162402), USP1 (ENSG00000162607), USP49 (ENSG00000164663), USP38 (ENSG00000170185), USP50 (ENSG00000170236), USP47 (ENSG00000170242)
Protein
Protein identifiers
Ubiquitin carboxyl-terminal hydrolase 17-like protein 1 — Q7RTZ2 (reviewed: Q7RTZ2)
Alternative names: Deubiquitinating enzyme 17-like protein 1, Ubiquitin thioesterase 17-like protein 1, Ubiquitin-specific-processing protease 17-like protein 1
All UniProt accessions (1): Q7RTZ2
UniProt curated annotations — full annotation on UniProt →
Function. Deubiquitinating enzyme that removes conjugated ubiquitin from specific proteins to regulate different cellular processes that may include cell proliferation, progression through the cell cycle, apoptosis, cell migration, and the cellular response to viral infection.
Subcellular location. Nucleus. Endoplasmic reticulum.
Similarity. Belongs to the peptidase C19 family. USP17 subfamily.
RefSeq proteins (1): NP_001243802* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR001394 | Peptidase_C19_UCH | Domain |
| IPR018200 | USP_CS | Conserved_site |
| IPR028889 | USP | Domain |
| IPR038765 | Papain-like_cys_pep_sf | Homologous_superfamily |
| IPR050164 | Peptidase_C19 | Family |
Pfam: PF00443
UniProt features (7 total): compositionally biased region 2, active site 2, chain 1, domain 1, region of interest 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q7RTZ2-F1 | 67.65 | 0.44 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Catalytic / active sites (2): 89 (nucleophile); 334 (proton acceptor)
Function
Pathways and Gene Ontology
Reactome pathways
1 pathways
| ID | Pathway |
|---|---|
| R-HSA-5689880 | Ub-specific processing proteases |
MSigDB gene sets: 14 (showing top):
GOBP_PROTEIN_MODIFICATION_BY_SMALL_PROTEIN_REMOVAL, GOMF_CYSTEINE_TYPE_PEPTIDASE_ACTIVITY, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_REGULATION_OF_PROTEIN_STABILITY, GOBP_PROTEOLYSIS, GOMF_PEPTIDASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_PEPTIDASE_ACTIVITY, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, REACTOME_DEUBIQUITINATION, REACTOME_UB_SPECIFIC_PROCESSING_PROTEASES, GOBP_REGULATION_OF_PROGRAMMED_CELL_DEATH, GOBP_PROTEIN_MODIFICATION_PROCESS, GOMF_DEUBIQUITINASE_ACTIVITY, chr8p23
GO Biological Process (5): proteolysis (GO:0006508), apoptotic process (GO:0006915), protein deubiquitination (GO:0016579), regulation of protein stability (GO:0031647), regulation of apoptotic process (GO:0042981)
GO Molecular Function (4): cysteine-type deubiquitinase activity (GO:0004843), peptidase activity (GO:0008233), cysteine-type peptidase activity (GO:0008234), hydrolase activity (GO:0016787)
GO Cellular Component (3): nucleus (GO:0005634), endoplasmic reticulum (GO:0005783), cytosol (GO:0005829)
Reactome top-level categories
Rollup of top-1 pathways:
| Category | Pathways |
|---|---|
| Deubiquitination | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| intracellular membrane-bounded organelle | 2 |
| cytoplasm | 2 |
| protein metabolic process | 1 |
| programmed cell death | 1 |
| apoptotic signaling pathway | 1 |
| execution phase of apoptosis | 1 |
| cysteine-type deubiquitinase activity | 1 |
| protein modification by small protein removal | 1 |
| regulation of biological quality | 1 |
| apoptotic process | 1 |
| regulation of programmed cell death | 1 |
| cysteine-type peptidase activity | 1 |
| deubiquitinase activity | 1 |
| hydrolase activity | 1 |
| catalytic activity, acting on a protein | 1 |
| peptidase activity | 1 |
| catalytic activity | 1 |
| endomembrane system | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
168 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| USP17L1 | FAM90A10 | A6NDY2 | 661 |
| USP17L1 | PRAMEF25 | A6NGN4 | 519 |
| USP17L1 | DEFB107A | Q8IZN7 | 479 |
| USP17L1 | XKR5 | Q6UX68 | 447 |
| USP17L1 | ZSCAN4 | Q8NAM6 | 430 |
| USP17L1 | DEFB108B | Q8NET1 | 400 |
| USP17L1 | ZNF735 | P0CB33 | 393 |
| USP17L1 | TMEM92 | Q6UXU6 | 380 |
| USP17L1 | PRR23B | Q6ZRT6 | 371 |
| USP17L1 | PRR23A | A6NEV1 | 370 |
| USP17L1 | PRR23D1 | E9PI22 | 370 |
| USP17L1 | DEFB105A | Q8NG35 | 339 |
| USP17L1 | Q3LFD5 | Q3LFD5 | 336 |
| USP17L1 | DEFB106A | Q8N104 | 332 |
| USP17L1 | USP54 | Q70EL1 | 325 |
IntAct
2 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| M | psi-mi:“MI:0914”(association) | 0.350 |
BioGRID (6): USP17L1 (Affinity Capture-MS), USP17L1 (Affinity Capture-MS), ATP5I (Cross-Linking-MS (XL-MS)), USP17L1 (Cross-Linking-MS (XL-MS)), USP17L1 (Affinity Capture-MS), USP17L1 (Affinity Capture-MS)
ESM2 similar proteins: A2A5N8, A6NCW0, A6NCW7, A8MUK1, B1AQJ2, B2RQC2, C9J2P7, C9JJH3, C9JLJ4, C9JPN9, C9JVI0, D3ZWK4, D6R901, D6R9N7, D6RA61, D6RBM5, D6RBQ6, D6RCP7, D6RJB6, E9Q9U0, G5E8G2, G5E8I7, O94966, P0C7H9, P0C7I0, P35125, P51784, Q0E2F9, Q0WX57, Q2TAC6, Q3UJD6, Q4KLL9, Q5R7G8, Q5TKR9, Q61068, Q66HE5, Q6J1Y9, Q6PFD6, Q6QN14, Q6R6M4
Diamond homologs: A1L1K8, A6NCW0, A6NCW7, A8MUK1, C9J2P7, C9JJH3, C9JLJ4, C9JPN9, C9JVI0, D6R901, D6R9N7, D6RA61, D6RBQ6, D6RCP7, D6RJB6, G1SW77, P0C7H9, P0C7I0, Q0WX57, Q5JVS0, Q5XJA5, Q6AXS5, Q6NRY1, Q6PB22, Q6R6M4, Q7RTZ2, Q8NC51, Q9CY58, Q9I9R0, Q9JKS5, A1CIL1, A1CW53, A2Q9N1, A4FUN7, A5D9H7, A5PJS6, A5WWB0, A6QR55, B0Y4P5, B2GUZ1
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
1 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 0 |
| Likely benign | 1 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
81 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:7333678:A:T | donor_gain | 0.5600 |
| 8:7333413:G:GT | donor_gain | 0.5500 |
| 8:7333423:G:GA | donor_gain | 0.5400 |
| 8:7333677:G:GT | donor_gain | 0.5300 |
| 8:7333485:GCC:G | donor_gain | 0.4700 |
| 8:7333660:TGGA:T | donor_gain | 0.4600 |
| 8:7333604:A:T | donor_gain | 0.4500 |
| 8:7333751:CGAAG:C | donor_loss | 0.4400 |
| 8:7333752:GAAG:G | donor_loss | 0.4400 |
| 8:7333753:AAG:A | donor_loss | 0.4400 |
| 8:7333754:AG:A | donor_loss | 0.4400 |
| 8:7333755:GGTAC:G | donor_loss | 0.4400 |
| 8:7333756:G:C | donor_loss | 0.4400 |
| 8:7333757:T:A | donor_loss | 0.4400 |
| 8:7332501:G:GC | acceptor_gain | 0.3900 |
| 8:7333503:A:AG | acceptor_gain | 0.3900 |
| 8:7333504:T:G | acceptor_gain | 0.3900 |
| 8:7333750:TCGAA:T | donor_loss | 0.3900 |
| 8:7333507:A:AG | acceptor_gain | 0.3800 |
| 8:7333508:G:GG | acceptor_gain | 0.3800 |
| 8:7333750:TCGA:T | donor_gain | 0.3800 |
| 8:7333508:GAAGA:G | acceptor_gain | 0.3700 |
| 8:7333368:TG:T | donor_gain | 0.3600 |
| 8:7333369:GG:G | donor_gain | 0.3600 |
| 8:7333508:GAA:G | acceptor_gain | 0.3500 |
| 8:7333130:A:T | donor_gain | 0.3400 |
| 8:7333758:A:C | donor_loss | 0.3400 |
| 8:7332594:C:CG | donor_gain | 0.3300 |
| 8:7332594:C:G | donor_gain | 0.3200 |
| 8:7333422:T:TA | donor_gain | 0.3200 |
AlphaMissense
3499 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:7332876:T:C | F164L | 0.880 |
| 8:7332878:T:A | F164L | 0.880 |
| 8:7332878:T:G | F164L | 0.880 |
| 8:7332843:T:C | F153L | 0.857 |
| 8:7332845:C:A | F153L | 0.857 |
| 8:7332845:C:G | F153L | 0.857 |
| 8:7333233:T:C | F283L | 0.850 |
| 8:7333235:C:A | F283L | 0.850 |
| 8:7333235:C:G | F283L | 0.850 |
| 8:7333497:T:C | F371L | 0.834 |
| 8:7333499:T:A | F371L | 0.834 |
| 8:7333499:T:G | F371L | 0.834 |
| 8:7332885:T:C | F167L | 0.832 |
| 8:7332887:C:A | F167L | 0.832 |
| 8:7332887:C:G | F167L | 0.832 |
| 8:7332975:T:C | F197L | 0.824 |
| 8:7332977:T:A | F197L | 0.824 |
| 8:7332977:T:G | F197L | 0.824 |
| 8:7333422:T:A | W346R | 0.741 |
| 8:7333422:T:C | W346R | 0.741 |
| 8:7333035:T:C | F217L | 0.679 |
| 8:7333037:T:A | F217L | 0.679 |
| 8:7333037:T:G | F217L | 0.679 |
| 8:7332902:G:A | M172I | 0.658 |
| 8:7332902:G:C | M172I | 0.658 |
| 8:7332902:G:T | M172I | 0.658 |
| 8:7333424:G:C | W346C | 0.631 |
| 8:7333424:G:T | W346C | 0.631 |
| 8:7333406:A:C | K340N | 0.618 |
| 8:7333406:A:T | K340N | 0.618 |
dbSNP variants (sampled 300 via entrez): RS1000492919 (8:7331782 A>T), RS1002166917 (8:7330892 A>G), RS1002302661 (8:7331064 C>G,T), RS1004085959 (8:7331474 C>G), RS1004117089 (8:7331346 C>A,G,T), RS1005438278 (8:7332751 G>A), RS1005739483 (8:7330564 T>G), RS1007975189 (8:7331736 G>A), RS1008422439 (8:7331521 T>C), RS1009010791 (8:7334060 AACACAC>A,AAC,AACAC,AACACACAC,AACACACACAC), RS1009684550 (8:7330614 C>A,T), RS1010064603 (8:7330857 G>A,C,T), RS1012495089 (8:7332674 G>A), RS1013552631 (8:7331243 G>C), RS1014583421 (8:7331117 T>A,C)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
3 total (human), top 3 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| triphenyltin | decreases expression | 1 |
| tributyltinisothiocyanate | decreases expression | 1 |
| Benzo(a)pyrene | increases expression | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.